➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Moodys
Dow
Express Scripts
Baxter

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,225,114

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,225,114
Title: Modified gene encoding glyphosate-tolerant 5-enolpruvyl-3-phosphoshikimate synthase
Abstract:DNA encoding glyphosate-tolerant 5-enolpyruvyl-3-phosphoshikimate (EPSP) synthases, plant genes encoding the glyphosate-tolerant enzymes, and plant transformation vectors containing the genes are disclosed. The DNA encodes glyphosate-tolerant EPSP synthases modified by substitution of an alanine residue for a glycine residue in a first conserved sequence found between positions 80 and 120, and a threonine residue for an alanine residue in a second conserved sequence found between positions 170 and 210 in the mature wild type EPSP synthase.
Inventor(s): Eichholtz; David Alan (St. Louis, MO), Gasser; Charles Scott (Davis, CA), Kishore; Ganesh Murthy (Chesterfield, MO)
Assignee: Monsanto Company (St. Louis, MO)
Application Number:09/243,374
Patent Claims:1. A DNA construct comprising in operative order:

(i) a promoter;

(ii) an intron;

(iii) a modified gene encoding a glyphosate-tolerant 5-enolpyruvyl-3-phosphoshikimate (EPSP) synthase enzyme with improved glyphosate tolerance wherein said modified gene comprises:

a first coding sequence encoding a first amino acid sequence:

-L-G-N-A-A-T-A (SEQ ID NO:26)

located between positions 80 and 120 of the mature EPSP synthase sequence encoded by said modified gene, and

a second coding sequence encoding a second amino acid sequence:

-A-L-L-M-x.sub.1 -A-P-L-T- (SEQ ID NO:27)

wherein x.sub.1 is either alanine, serine or threonine, and wherein said second amino acid sequence is located between positions 170 and 210 of the mature EPSP synthase sequence encoded by said modified gene; and

(iv) a 3' termination sequence;

wherein said promoter is heterologous to said modified gene.

2. The DNA construct of claim 1 wherein said intron is the maize ADH1 intron.

3. The DNA construct of claim 1 wherein said promoter is selected from the group consisting of the CaMV35S promoter, a FMV promoter, and the ssRUBISCO promoter.

4. The DNA construct of claim 1 wherein said modified gene is obtained by:

isolating a gene encoding a 5-enolpyruvyl-3-phosphoshikimate (EPSP) synthase enzyme from a plant or bacterium selected from the group consisting of petunia, tomato, maize, Arabidopsis thaliana, soybean, Brassica napus, E. coli K-12, and Salmonella typhimurium; and

mutating said gene to produce said modified gene comprising said first coding sequence and said second coding sequence.

5. The DNA construct of claim 1 wherein said intron is the maize ADH1 intron and said modified gene encoding a glyphosate-tolerant 5-enolpyruvyl-3-phosphoshikimate (EPSP) synthase enzyme is derived from a gene isolated from maize.

6. A transformation vector comprising the DNA construct of any one of claims 1, 2, 3, 4, or 5.

Details for Patent 6,225,114

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Monsanto Company (St. Louis, MO) 2010-09-28 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Monsanto Company (St. Louis, MO) 2010-09-28 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Monsanto Company (St. Louis, MO) 2010-09-28 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Harvard Business School
Express Scripts
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.